Reading NUWE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NUWE free→Reading NUWE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NUWE free→QuarterlyIQ Insights · NUWE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 12, 2026, Nuwellis, Inc. (the “Company”) issued a press release reporting its financial results for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in the Initial Filing, on March 26, 2026, each of Mika Grasso and Katharyn Field resigned, effective immediately, from the Board. Copies of their resignation letters were attached as exhibits to the Initial Filing. On March 31, 2026, each of Katharyn Field and Mika Grasso provided supplemental letters to the Company’s Initia…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2026, each of Mika Grasso and Katharyn Field resigned, effective immediately, from the Board of Directors (the “ Board ”) of Nuwellis, Inc. (the “ Company ”). Mr. Grasso resigned due to the matters set forth in his resignation letter, which details various disagreements with the Company, including the Company’s and its advisors’ allege…
Other Events. On March 17, 2026, Nuwellis, Inc. (the “ Company ”) announced the closing of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Da…
Results of Operations and Financial Condition. On March 10, 2026, Nuwellis, Inc. (the “Company”) issued a press release reporting its financial results for the three and twelve months ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to
Results of Operations and Financial Condition. On November 12, 2025, Nuwellis, Inc. (the “Company”) issued a press release reporting its financial results for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Chief Financial Officer On October 7, 2025, Robert B. Scott notified Nuwellis, Inc., a Delaware corporation (the “ Company ”) of his decision to resign as the Chief Financial Officer of the Company. Mr. Scott’s last date with the Company is expected to be on or about October 24, 2025 (the “ Separation Date ”). Mr. Scott’s resignation…
Entry into a Material Definitive Agreement. On September 3, 2025, the Company entered into an At The Market Offering Agreement (the “ Sales Agreement ”) with Ladenburg Thalmann & Co. Inc. (“ Ladenburg ”) pursuant to which the Company may sell shares of the Company’s common stock, par value $0.0001 (the “ Common Stock ”), from time to time, at its option, through or to Ladenburg, as sales agent or principal. Sales of the Company’s Common Stock made pursuant to the Sales Agreement, if any, will…
Other Events. On August 19, 2025, Nuwellis, Inc. (the “ Company ”) announced that it has entered into a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli-based medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies. The proposed acquisition is expected to support the Company’s strategy to expand its current technology platform beyond ultrafiltration by potentially adding continuous renal health monitoring technologies tha…
Results of Operations and Financial Condition. On August 14, 2025, Nuwellis, Inc. (the “Company”) issued a press release reporting its financial results for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 27, 2025, the board of directors (the “ Board ”) of Nuwellis, Inc. (the “Company” ) appointed John L. Erb as the Company’s Chief Executive Officer and President. As previously disclosed, Mr. Erb was appointed as interim Chief Executive Officer and CEO in February 2025. Mr. Erb, age 76, has served as a director of the Company since September…
Material Modification to Rights of Security Holders. To the extent required by
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 18, 2025, Nuwellis, Inc. (the “Company” ) received a letter (the “Deficiency Notice” ) from the Listing Qualifications Department (the “Staff” ) of the Nasdaq Stock Market ( “Nasdaq” ) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minim…
Entry into a Material Definitive Agreement. The information included in
Unregistered Sales of Equity Securities. The information included in
Results of Operations and Financial Condition. On May 13, 2025, Nuwellis, Inc. (the “Company”) issued a press release reporting its financial results for the three months ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to
Entry into a Material Definitive Agreement. On May 9, 2025 (the “ Effective Date ”), Nuwellis, Inc. (the “ Company ”) entered into a Supply & Quality Agreement (the “ Supply Agreement ”) with Kluge Design, LLC, a Minnesota limited liability company (“ KDI ”), pursuant to which KDI will manufacture the Aquadex Blood Circuit, Aquadex dELC Catheter and Aquadex SmartFlow Console (the “ Aquadex ”) and perform related calibration and repair services. The Company will retain exclusive ownership of t…
Results of Operations and Financial Condition. On March 11, 2025, Nuwellis, Inc. (the “Company”) issued a press release reporting its financial results for the three and twelve months ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Executive Officer On February 24, 2025, Nuwellis, Inc. (the “Company” ) announced that Nestor Jaramillo, Jr. is retiring from the Company, effective February 18, 2025 (“ Retirement Date ”). Pursuant to a Separation and Release Agreement entered into between the Company on February 23, 2025 (the “ Separation Agreement ”), Mr. Jara…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.